Karen Basbaum

Ms. Basbaum is our Vice President of Business Development and has served in this position since July 2020. Prior to joining Poseida, Karen held positions in drug discovery and business development for several biotechnology and large pharmaceutical companies.

Karen joined Poseida from DNAtrix, a biotechnology company developing oncolytic viruses for the treatment of cancer, where she was Senior Vice President of Business Development. Prior to that role, Karen was VP of Business Development at both Dauntless Pharmaceuticals and Elcelyx Therapeutics and Director, Business Development at Amylin Pharmaceuticals where she worked on numerous transactions, most notably the sale of the company to Bristol Myers Squibb in 2012 for $7B. Earlier in her career, Karen held various scientific roles in drug discovery at Abbott Laboratories (now Abbvie) and Celgene Corporation.